High-density lipoprotein: does it have a dark side?
There are proven pleiotropic anti-atherogenic actions of high-density lipoprotein (HDL). However, in systemic inflammation, HDL can have pro-inflammatory properties that may contribute to accelerated atherosclerosis, likely mediated by a change in the structure of HDL to pro-inflammatory HDL (PiHDL). Validation of the technically challenging assay for PiHDL, and confirmation of an association of PiHDL in multiple populations with known risk for atherosclerosis will eventually provide a useful biomarker. Identification of PiHDL in patients with rheumatic disease may help identify patients at risk of accelerated atherosclerosis, and focus our therapeutic interventions.
Von Feldt
Joan M
JM
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000009:adverse effects* / Q000737:chemistry / Q000378:metabolism
D008075:Lipoproteins, HDL